solventum corp. - SOLV
SOLV
Close Chg Chg %
85.25 0.15 0.18%
Closed Market
85.40
+0.15 (0.18%)
Volume: 1.12M
Last Updated:
Dec 5, 2025, 3:59 PM EDT
Company Overview: solventum corp. - SOLV
SOLV Key Data
| Open $84.63 | Day Range 84.63 - 85.89 |
| 52 Week Range 60.70 - 88.19 | Market Cap $14.79B |
| Shares Outstanding 173.45M | Public Float 147.61M |
| Beta 0.46 | Rev. Per Employee N/A |
| P/E Ratio 9.81 | EPS $8.74 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.22M |
SOLV Performance
| 1 Week | 0.20% | ||
| 1 Month | 19.45% | ||
| 3 Months | 17.48% | ||
| 1 Year | 22.11% | ||
| 5 Years | N/A |
SOLV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About solventum corp. - SOLV
Solventum Corp. operates as a health care company. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.
SOLV At a Glance
Solventum Corp.
3M Center
Maplewood, Minnesota 55144
| Phone | 1-651-733-1110 | Revenue | 8.25B | |
| Industry | Medical/Nursing Services | Net Income | 479.00M | |
| Sector | Health Services | 2024 Sales Growth | 0.695% | |
| Fiscal Year-end | 12 / 2025 | Employees | 22,000 | |
| View SEC Filings |
SOLV Valuation
| P/E Current | 9.813 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.956 |
| Price to Sales Ratio | 1.39 |
| Price to Book Ratio | 3.857 |
| Price to Cash Flow Ratio | 9.68 |
| Enterprise Value to EBITDA | 11.607 |
| Enterprise Value to Sales | 2.289 |
| Total Debt to Enterprise Value | 0.433 |
SOLV Efficiency
| Revenue/Employee | 375,181.818 |
| Income Per Employee | 21,772.727 |
| Receivables Turnover | 6.716 |
| Total Asset Turnover | 0.581 |
SOLV Liquidity
| Current Ratio | 1.202 |
| Quick Ratio | 0.845 |
| Cash Ratio | 0.282 |
SOLV Profitability
| Gross Margin | 55.876 |
| Operating Margin | 13.303 |
| Pretax Margin | 7.33 |
| Net Margin | 5.803 |
| Return on Assets | 3.373 |
| Return on Equity | 6.55 |
| Return on Total Capital | 4.299 |
| Return on Invested Capital | 4.241 |
SOLV Capital Structure
| Total Debt to Total Equity | 276.546 |
| Total Debt to Total Capital | 73.443 |
| Total Debt to Total Assets | 56.602 |
| Long-Term Debt to Equity | 266.847 |
| Long-Term Debt to Total Capital | 70.867 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Solventum Corp. - SOLV
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 8.17B | 8.13B | 8.20B | 8.25B | |
Sales Growth
| - | -0.50% | +0.82% | +0.70% | |
Cost of Goods Sold (COGS) incl D&A
| 3.25B | 3.44B | 3.50B | 3.64B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 597.00M | 578.00M | 561.00M | 530.00M | |
Depreciation
| 184.00M | 177.00M | 164.00M | 181.00M | |
Amortization of Intangibles
| 413.00M | 401.00M | 397.00M | 349.00M | |
COGS Growth
| - | +5.76% | +2.01% | +3.94% | |
Gross Income
| 4.92B | 4.70B | 4.69B | 4.61B | |
Gross Income Growth
| - | -4.63% | -0.04% | -1.73% | |
Gross Profit Margin
| +60.25% | +57.75% | +57.25% | +55.88% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 3.04B | 3.00B | 3.00B | 3.51B | |
Research & Development
| 766.00M | 767.00M | 758.00M | 768.00M | |
Other SG&A
| 2.28B | 2.23B | 2.24B | 2.75B | |
SGA Growth
| - | -1.38% | -0.03% | +17.09% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 62.00M | - |
EBIT after Unusual Expense
| 1.88B | 1.69B | 1.69B | 1.04B | |
Non Operating Income/Expense
| 3.00M | (1.00M) | (25.00M) | (64.00M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 367.00M | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | 367.00M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.88B | 1.69B | 1.67B | 605.00M | |
Pretax Income Growth
| - | -10.10% | -1.48% | -63.71% | |
Pretax Margin
| +23.03% | +20.81% | +20.34% | +7.33% | |
Income Tax
| 422.00M | 349.00M | 321.00M | 126.00M | |
Income Tax - Current - Domestic
| 346.00M | 408.00M | 192.00M | 137.00M | |
Income Tax - Current - Foreign
| 114.00M | 82.00M | 271.00M | 144.00M | |
Income Tax - Deferred - Domestic
| (54.00M) | (135.00M) | (17.00M) | (145.00M) | |
Income Tax - Deferred - Foreign
| 16.00M | (6.00M) | (125.00M) | (10.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 1.46B | 1.34B | 1.35B | 479.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 1.46B | 1.34B | 1.35B | 479.00M | |
Net Income Growth
| - | -8.01% | +0.22% | -64.41% | |
Net Margin Growth
| +17.87% | +16.52% | +16.42% | +5.80% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 1.46B | 1.34B | 1.35B | 479.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.46B | 1.34B | 1.35B | 479.00M | |
EPS (Basic)
| 8.4535 | 7.7761 | 7.7934 | 2.7656 | |
EPS (Basic) Growth
| - | -8.01% | +0.22% | -64.51% | |
Basic Shares Outstanding
| 172.71M | 172.71M | 172.71M | 173.20M | |
EPS (Diluted)
| 8.4535 | 7.7761 | 7.7934 | 2.7576 | |
EPS (Diluted) Growth
| - | -8.01% | +0.22% | -64.62% | |
Diluted Shares Outstanding
| 172.71M | 172.71M | 172.71M | 173.70M | |
EBITDA
| 2.48B | 2.27B | 2.25B | 1.63B | |
EBITDA Growth
| - | -8.28% | -0.79% | -27.74% | |
EBITDA Margin
| +30.30% | +27.93% | +27.49% | +19.72% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 84.111 | |
| Number of Ratings | 14 | Current Quarters Estimate | 1.493 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 6.022 | |
| Last Quarter’s Earnings | 1.50 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 6.70 | Next Fiscal Year Estimate | 6.363 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 9 | 12 | 12 |
| Mean Estimate | 1.49 | 1.48 | 6.02 | 6.36 |
| High Estimates | 1.51 | 1.54 | 6.05 | 6.50 |
| Low Estimate | 1.47 | 1.43 | 6.00 | 6.20 |
| Coefficient of Variance | 0.81 | 2.86 | 0.24 | 1.32 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 8 | 8 | 9 |
| UNDERWEIGHT | 1 | 1 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Solventum Corp. - SOLV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Solventum Corp. - SOLV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2025 | Bryan C. Hanson Chief Executive Officer; Director | 95,723 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Wayde Dwight McMillan Chief Financial Officer | 26,407 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | J. Christopher Barry Executive Vice President | 19,805 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Amy Landucci Chief Information Officer | 11,388 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Marcela A. Kirberger Chief Legal Affairs Officer | 12,543 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Tammy L. Gomez Chief Human Resources Officer | 9,903 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Paul Harrington Chief Supply Chain Officer | 9,903 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |